Zhonghua Yi Xue Za Zhi. 2026 Jan 5;106:18-36. doi: 10.3760/cma.j.cn112137-20250804-01959. Online ahead of print.
ABSTRACT
Panvascular disease is a systemic condition characterized by atherosclerotic lesions as its common pathological feature. It may present as coronary artery disease, cerebrovascular disease, peripheral artery disease, or polyvascular disease, which is defined as the involvement of two or more vascular beds. As a leading cause of death in China, panvascular disease imposes a substantial health burden worldwide. Dyslipidemia is a well-established key risk factor for the initiation and progression of atherosclerosis. Current challenges in lipid management among patients with panvascular disease in China include insufficient awareness, suboptimal achievement of treatment targets, and inadequate multidisciplinary coordination. There is a pressing need to develop lipid-lowering strategies tailored to the characteristics of the Chinese population. To address this gap, a panel of experts in cardiology, endocrinology, neurology, and vascular surgery developed the "Chinese Expert Consensus on Lipid Management for Panvascular Disease". This consensus is based on a comprehensive review of the latest clinical evidence and guidelines from both domestic and international literature. It emphasizes standardized management of dyslipidemia in patients with panvascular disease, offering recommendations on risk stratification assessment, lipid target values, lifestyle modifications, and pharmacologic treatment. The document aims to provide clinicians with practical, evidence-based guidance for individualized lipid management, with the ultimate goal of reducing atherosclerotic cardiovascular events and improving long-term outcomes.
PMID:41500966 | DOI:10.3760/cma.j.cn112137-20250804-01959